Cargando…
Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19
PURPOSE: End-organ damage in coronavirus disease-2019 (COVID-19) is linked to “cytokine storm” and excessive release of inflammatory mediators. Various novel therapies have been used in COVID-19 including urinary trypsin inhibitor therapy. This study explores the efficacy of ulinastatin in COVID-19....
Autores principales: | Jain, Ashish, Kasliwal, Rajeev, Jain, Srishti Suresh, Jain, Rohit, Gupta, Divyansh, Gupta, Priyamvada, Jain, Anand, Tambi, Rohan, Panwar, Puneet, Meena, Munesh, Jain, Ravi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Jaypee Brothers Medical Publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237140/ https://www.ncbi.nlm.nih.gov/pubmed/35836625 http://dx.doi.org/10.5005/jp-journals-10071-24156 |
Ejemplares similares
-
Providencia Causing Urinary Tract Infections: Are We Reaching a Dead End?
por: Rajni, Ekadashi, et al.
Publicado: (2022) -
Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study
por: Karnad, Dilip R., et al.
Publicado: (2014) -
Blood donor deferral periods after COVID-19 vaccination
por: Gupta, Abhaykumar Malind, et al.
Publicado: (2021) -
Influence of Light Energy Density, Composite Type, Composite Thickness, and Postcuring Phase on Degree of Conversion of Bulk-fill Composites
por: Jain, Lipika, et al.
Publicado: (2018) -
Efficacy of Ulinastatin and Sulforaphane Alone or in Combination in Rat Model of Streptozotocin Diabetes Induced Vascular Dementia
por: Sharma, Poonam, et al.
Publicado: (2021)